These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23337708)

  • 1. Evaluation of a bedside device to assess the activated partial thromboplastin time for heparin monitoring in infants.
    Klein RH; van der Vorst MM; de Wilde RB; Hogenbirk K; de Kam ML; Burggraaf J
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):327-31. PubMed ID: 23337708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the activated partial thromboplastin time for heparin monitoring.
    Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC
    Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point of care and central laboratory determinations of the aPTT are not interchangeable in surgical intensive care patients.
    Ferring M; Reber G; de Moerloose P; Merlani P; Diby M; Ricou B
    Can J Anaesth; 2001 Dec; 48(11):1155-60. PubMed ID: 11744594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The accuracy of a point of care measurement of activated partial thromboplastin time in intensive care patients.
    Karigowda L; Deshpande K; Jones S; Miller J
    Pathology; 2019 Oct; 51(6):628-633. PubMed ID: 31445807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bedside coagulometry during intravenous heparin therapy after coronary angioplasty.
    Schroeder AP; Knudsen LL; Husted SE; Knudsen L; Ingerslev J
    J Thromb Thrombolysis; 2001 Oct; 12(2):157-63. PubMed ID: 11729367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
    Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
    Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring the effects of heparin: evaluation of a new portable device.
    Cavanagh SP; Haine L; Ammori B; Tate G; Braithwaite P; Gough MJ; Homer-Vanniasinkam S
    Cardiovasc Surg; 1998 Oct; 6(5):496-9. PubMed ID: 9794270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of point-of-care activated partial thromboplastin time testing by comparison to laboratory-based assay for control of intravenous heparin.
    Douglas AD; Jefferis J; Sharma R; Parker R; Handa A; Chantler J
    Angiology; 2009; 60(3):358-61. PubMed ID: 19398428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a bedside activated clotting time test (Hemochron Jr II Signature) with low dose heparin therapy.
    Racioppi L; Quinart A; Biais M; Nouette-Gaulain K; Revel P; Sztark F
    Anaesthesia; 2009 Apr; 64(4):430-4. PubMed ID: 19317710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between activated clotting time and activated partial thromboplastin times.
    Smythe MA; Koerber JM; Nowak SN; Mattson JC; Begle RL; Westley SJ; Balasubramaniam M
    Ann Pharmacother; 2002 Jan; 36(1):7-11. PubMed ID: 11816262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disagreement between bedside and laboratory activated partial thromboplastin time and international normalized ratio for various novel anticoagulants.
    Kemme MJ; Faaij RA; Schoemaker RC; Kluft C; Meijer P; Cohen AF; Burggraaf J
    Blood Coagul Fibrinolysis; 2001 Oct; 12(7):583-91. PubMed ID: 11685048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation.
    Maul TM; Wolff EL; Kuch BA; Rosendorff A; Morell VO; Wearden PD
    Pediatr Crit Care Med; 2012 Nov; 13(6):e363-71. PubMed ID: 22940857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New bedside test for monitoring anticoagulation during hemodialysis.
    Eiswirth G; Walch S; Bommer J
    Artif Organs; 1998 Apr; 22(4):346-8. PubMed ID: 9555967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S; Preston FE
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of activated partial thromboplastin time (aPTT) reagents for application in biomedical diagnostic device development.
    Dudek MM; Harris LF; Killard AJ
    Int J Lab Hematol; 2011 Jun; 33(3):272-80. PubMed ID: 21118388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of the activated clotting time for monitoring heparin therapy in critically ill patients.
    De Waele JJ; Van Cauwenberghe S; Hoste E; Benoit D; Colardyn F
    Intensive Care Med; 2003 Feb; 29(2):325-8. PubMed ID: 12594595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.
    van den Besselaar AM; Meeuwisse-Braun J; Bertina RM
    Thromb Haemost; 1990 Feb; 63(1):16-23. PubMed ID: 2339357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring unfractionated heparin with APTT: a French collaborative study comparing sensitivity to heparin of 15 APTT reagents.
    Gouin-Thibaut I; Martin-Toutain I; Peynaud-Debayle E; Marion S; Napol P; Alhenc-Gelas M;
    Thromb Res; 2012 May; 129(5):666-7. PubMed ID: 22169771
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of instrumentation and laboratory site on the accuracy of the APTT-based heparin therapeutic range.
    Marlar RA; Gausman JN
    Int J Lab Hematol; 2012 Dec; 34(6):614-20. PubMed ID: 22712447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.